<DOC>
	<DOCNO>NCT00969722</DOCNO>
	<brief_summary>This multicenter , randomize , control , open-label study . Patients meet inclusion/exclusion criterion randomize ( 1:1 ) receive two cycle MAb-3F8 plus GM-CSF RA plus GM-CSF . Patients respond assign treatment two cycle may cross-over receive alternate treatment . Disease response safety assess patient cycle 2 cycle 4 .</brief_summary>
	<brief_title>A Study MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) Versus 13-cis-Retinoic Acid ( RA ) Plus GM-CSF Primary Refractory Neuroblastoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Have diagnosis stage 4 neuroblastoma diagnose accordance International Neuroblastoma Staging System : either ( ) histologic confirmation may involve immunohistochemical , ultrastructural , and/or cytogenetic study , ( b ) elevate urinary catecholamine plus tumor cells/clumps bone marrow . Have evaluable disease biopsyproven stable disease BM histology MIBG scan MIBGpositive disease confine bone bone marrow , plus urine catecholamine result , document &gt; 3 week conventional chemotherapy &gt; 6 week stemcell transplantation . CT , MRI , bone scan ( necessary ) do 23 week conventional chemotherapy confirm chemotherapy , radiotherapy , ABMT realistic curative option . Be 18 month 13 year old diagnosis . Have recover grade 2 good toxicity since prior therapy . Must , female childbearing potential , willing use two form medically acceptable contraception ( least one barrier method ) negative pregnancy test screen monthly thereafter first four cycle treatment . Have performance score least 60 Lansky Play Performance Scale age 16 year least 60 Karnofsky Scale age 16 year . Have voluntarily agree participate . Have measurable disease â‰¥ 1 cm assess CT MRI . Have progressive disease ( new lesion ; increase measurable lesion &gt; 25 % ; previous negative marrow positive tumor ) . Have disease detectable CNS ( confirm CT MRI brain screening within 8 week randomization ) . Be receive alternative therapy treatment neuroblastoma , e.g . radiotherapy chemotherapy within 3 week randomization . Require additional therapy ( radiotherapy ) first two treatment cycle . Have detectable human antimouse antibody titer screen . Have receive prior antiGD2 investigational therapy . Have history allergy mouse protein . Have active infection require IV infusion antibiotic . Be currently receive longterm chronic treatment immunosuppressive drug cyclosporine , adrenocorticotropic hormone ( ACTH ) , systemic corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>3F8</keyword>
	<keyword>Primary refractory</keyword>
</DOC>